Clik here to view.
Allergan’s intravitreal implant wins approval in China
Allergan (NYSE:AGN) said today that it landed an imported drugs license from the Chinese FDA to market its dexamethasone intravitreal implant, Ozurdex, as a treatment for adults with macular edema...
View ArticleClik here to view.
Cordis inks exclusive distribution deal for Medinol’s coronary stent...
Cordis has inked an exclusive distribution deal to sell Medinol‘s coronary stents in the U.S., the company reported, adding a cobalt-chromium bare-metal stent and a drug-eluting stent to its portfolio....
View ArticleClik here to view.
Novaliq’s NovaTears dry eye disease therapy launches in New Zealand
Novaliq today launched its dry eye disease therapy, NovaTears, in New Zealand and said that it won registrational approval in Australia. The Germany-based company inked an exclusive licensing...
View ArticleClik here to view.
TCT 2017: Abbott’s Xience coronary stent helps patients feel better faster...
Abbott (NYSE:ABT) reported today that patients who were treated with the company’s Xience coronary stent for left-main coronary artery disease felt better faster compared to patients who had open-heart...
View ArticleClik here to view.
Elixir Medical unveils ‘bioadaptive’ metallic drug-eluting stent at TCT 2017
Interventional cardiologists have used stents to keep the heart’s coronary arteries open for decades. Transitioning from bare-metal stents to drug-eluting stents in the early 2000s brought tremendous...
View ArticleClik here to view.
TCT 2017: OrbusNeich’s dual therapy stent non-inferior to Abbott’s Xience DES...
OrbusNeich touted results today from a pivotal registration study comparing its Combo dual therapy stent with Abbott‘s (NYSE:ABT) Xience stent in patients with ischemic heart disease. The trial is...
View ArticleClik here to view.
Agile Therapeutics touts late-stage trial for once-weekly contraceptive patch
Agile Therapeutics (NSDQ:AGRX) touted data today from a Phase III trial of its once-weekly, low-dose hormonal contraceptive patch, Twirla. The study showed that women experienced mean decreases in...
View ArticleClik here to view.
Pfizer posts Street-beating Q3, raises full-year earnings forecast
Shares in Pfizer (NYSE:PFE) fell slightly today even though the pharmaceutical giant beat expectations on Wall Street with its third quarter results. The New York-based company posted profits of $2.84...
View ArticleClik here to view.
Study: Glooko’s mobile app boosts glycemic control in patients with Type II...
Glooko touted data today from a feasibility study evaluating the impact of its mobile insulin dosing system for people with Type II diabetes who are taking long-acting insulin. The Mountain View,...
View ArticleNovo Nordisk shares slip on cautious guidance, insulin pricing concerns
The post Novo Nordisk shares slip on cautious guidance, insulin pricing concerns appeared first on MassDevice.
View ArticleLong-term data for Abbott’s Absorb “highlight the need for continued...
The post Long-term data for Abbott’s Absorb “highlight the need for continued improvements” in BRS tech appeared first on MassDevice.
View ArticleOne Drop partners with Fitbit to bring diabetes data to people’s wrists
The post One Drop partners with Fitbit to bring diabetes data to people’s wrists appeared first on MassDevice.
View ArticleReva, Biotronik tout safety data for their drug-eluting bioresorbable scaffolds
The post Reva, Biotronik tout safety data for their drug-eluting bioresorbable scaffolds appeared first on MassDevice.
View ArticleAdvisory committee backs Indivior’s once-monthly opioid use disorder treatment
The post Advisory committee backs Indivior’s once-monthly opioid use disorder treatment appeared first on MassDevice.
View ArticleClik here to view.
Here’s how Amaranth Medical plans to get ahead with its bioresorbable...
There are two ways to make a bioresorbable, drug-eluting scaffold, according to Amaranth Medical CEO Kamal Ramzipoor. “The Amaranth way, or the conventional way, which our competition is using,” he...
View ArticleClik here to view.
Biotronik’s Orsiro drug-eluting stent succeeds at five-year follow-up
Biotronik touted long-term safety and efficacy data for its Orsiro drug-eluting stent yesterday at this year’s Transcatheter Cardiovascular Therapeutics meeting. Data from the Bioflow-II trial and the...
View ArticleClik here to view.
TCT 2017: Medtronic & OrbusNeich evaluate shortening dual antiplatelet...
At this year’s Transcatheter Cardiovascular Therapeutics meeting, companies presented work comparing shortened durations of dual anti-platelet therapy with the standard 1-year regimen in patients...
View ArticleClik here to view.
Dexcom beats earnings estimate by 12 cents in Q3
Shares in Dexcom (NSDQ:DXCM) soared today after the medical device maker topped expectations on Wall Street with its third quarter results. The San Diego, Calif.-based company posted a net loss of -$2...
View ArticleClik here to view.
Report: Seven deaths from EpiPen failures this year
Defective EpiPens have been cited in seven deaths this year so far, according to reports made to the FDA and obtained by Bloomberg News. During the same period, the FDA has received 228 reports of...
View ArticleClik here to view.
TCT 2017: Drug-eluting balloon achieves non-inferiority with drug-eluting stent
Researchers studying 278 patients with in-stent restenosis found that B. Braun‘s SeQuent Please paclitaxel-eluting balloon was non-inferior to Abbott‘s (NYSE:ABT) Xience drug-eluting stent when it...
View Article